Stereotaxis (STXS) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Stereotaxis in July 2026.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, it offers its customers x-ray systems and other accessory devices. It also provides robotic technologies for interventional cardiology and neuro-interventions. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Stereotaxis stock, which has a target price of $4.6, indicating growth potential.
Financial Health
Stereotaxis is performing well with solid revenue and cash flow, supported by a healthy gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring STXS
Boston Scientific Penumbra Deal (Cardiovascular M&A)
Boston Scientific is set to acquire Penumbra for $14.5 billion, marking a significant expansion into the high-growth thrombectomy and neurovascular device markets. This major consolidation could catalyze further M&A activity, creating investment opportunities among other innovative companies in the cardiovascular sector.
Published: 17 January 2026
Explore BasketWhy invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
